
Peptide based cancer therapeutics are yet to become widespread, but the initial low numbers certainly do not suggest any pessimism in the global market. With new developments in delivery, stability, modifications, and preclinical success, future growth potentials of such cancer therapeutics continue to intensify. A slew of new peptides with positive preclinical results are entering into clinical trials that are focused on cancer treatment. Moreover, the application base of peptides is steadily expanding to other therapeutic areas as well. In the near future, the global peptide based cancer therapeutics market is likely to be influenced by the rising prevalence of cancer across the globe. WHO reveals that cancer is one of the leading causes of death worldwide, which accounted for more than 8 million deaths in 2015. Factor as such are expected to play an important role in boosting the popularity of peptide based cancer therapeutics further. In addition, various complications involved in conventional cancer therapeutics as well as the risk of sever side-effects are prompting medical professionals to utilise peptides in tumor and cancer treatment. Fact.MR's latest report projects that the global peptide based cancer therapeutics market will surpass a valuation of US$ 11,160 Mn by 2022-end, expanding at an impressive CAGR of 9.2% during the forecast period (2017-2022).